UPDATE: Morgan Stanley Reiterates Equal-Weight Rating, Removes PT on Regeneron Pharmaceuticals Ahead of Conference Call

Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on
Regeneron PharmaceuticalsREGN
, but removed the $310.00 price target. In the report, Morgan Stanley noted, “We believe positive data is already priced into REGN and expect minimal impact. While there could be some investor enthusiasm around the CV data, we do not believe alirocumab could differentiate itself from evolocumab on such a small study and further believe any positive CV data would be viewed as a class effect. Our ~$2B in 2020E WW alirocumab sales already reflects positive LDL lowering data, though we note positive outcomes data could double our ests. We look forward to any additional details on Regeneron and Sanofi's 8:30 AM EST Tuesday conference call.” Regeneron Pharmaceuticals closed on Friday at $350.46.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMatthew HarrisonMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...